PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
June 11, 2026RSC Medicinal Chemistry

Discovery of a Potent Dual Target CDK8 and Cyclic C PROTAC Degrader for Treatment of Colorectal Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXingxing ZhangQCQingsong ChenCLCencen Lei

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates effectiveness of CDK8 and Cyclic C PROTAC degrader in colorectal cancer, indicating strong therapeutic potential.

Key Points

  • The study aims to identify a novel dual-target PROTAC degrader that effectively targets CDK8 and Cyclic C for colorectal cancer treatment.
  • Developed a PROTAC molecule targeting CDK8 and Cyclic C.
  • Evaluated its effects on colorectal cancer cell lines through biochemical assays.
  • Assessed the physiological interactions within signaling pathways.
  • The PROTAC degrader significantly reduced CDK8 levels in vitro with a corresponding decrease in cancer cell viability.
  • Demonstrated enhanced degradation of both CDK8 and Cyclic C, leading to altered cellular signaling.
  • Observed effective anti-tumor activity in preclinical models, highlighting its therapeutic promise.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a2a50e080c8f91e7f39d4eahttps://doi.org/10.1039/d6md00281a
View Full Paper
Ask AI
Bookmark
Share